- Home
- MLYS vs DNTH Comparison
MLYS vs DNTH Comparison
Compare MLYS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLYS | DNTH |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.8B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MLYS | DNTH |
|---|---|---|
| Price | $37.39 | $43.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $47.33 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 1.5M | 678.9K |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,078,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $13.37 |
| 52 Week High | $47.65 | $45.46 |
Technical Indicators
Market Signals| Indicator | MLYS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 57.17 |
| Support Level | $36.01 | $42.02 |
| Resistance Level | $38.23 | $44.00 |
| Average True Range (ATR) | 1.77 | 1.77 |
| MACD | 0.07 | -0.24 |
| Stochastic Oscillator | 42.59 | 60.83 |
Price Performance
Historical ComparisonAbout MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.